Ranolazine (Ranexa) – Rough “Plant‑Build” Cost Estimates
Below is a high‑level, ball‑park picture of what it takes to set up a GMP‑compliant manufacturing facility that could produce the active pharmaceutical ingredient (API) Ranolazine (the active moiety in Ranexa®). All figures are illustrative only – real‐world costs will depend on a wide variety of factors, many of which are confidential to the parties involved.
| Scale / Scope |
Typical Cost Range |
Key Cost Drivers |
| Small‑scale, 5‑10 % of commercial volume (≈ 10–20 kg/day) |
$7 – 15 million |
• Basic GMP‑grade building + lab space
• Core equipment (reactor, distillation, filtration, drying, packaging)
• Initial regulatory submissions (e.g., IND, GMP dossier)
• Limited quality‑control labs |
| Mid‑scale, 10‑50 % of commercial volume (≈ 50–200 kg/day) |
$15 – 40 million |
• Larger building, more robust utilities (copper, stainless steel, clean‑room air handling)
• Expanded analytical & QC labs
• Automation (pumps, mixers, robots)
• More comprehensive quality‑assurance and documentation systems |
| Large‑scale, > 50 % of commercial volume (≥ 200 kg/day) |
$40 – 120 million (or higher) |
• Dedicated production lines with multiple reactors and parallel purification modules
• Advanced process analytical technology (PAT) and in‑line monitoring
• Full‑scale quality‑control & stability labs
• Extensive safety & environmental controls (spill containment, waste treatment, flammability protection)
• Higher regulatory burden (e.g., full GMP, CAPA, change‑control systems) |
What goes into the cost?
| Component |
Typical Cost |
What it Covers |
| Real estate & construction |
30–50 % of total |
Site acquisition, site prep, building, HVAC, clean‑room infrastructure |
| Equipment |
20–35 % |
Reactors, distillation units, chromatography columns, drying ovens, analytical instruments |
| Utilities & services |
10–20 % |
Power, water, compressed air, HVAC, waste‑treatment infrastructure |
| Quality & regulatory |
10–15 % |
GMP compliance training, documentation, validation, CAPA, quality‑systems software |
| Other |
5–10 % |
Project management, contingency, legal, permits, insurance |
Note: These percentages are derived from industry‑wide averages for pharma manufacturing facilities. For Ranolazine specifically, the “process‑specific” cost of the API synthesis (e.g., reagents, catalysts, solvents) is typically $2‑$8 per gram of API, depending on route optimization and raw‑material sourcing. However, the facility cost is largely independent of the API itself – it reflects the capacity, the required clean‑room level, and the regulatory environment.
Regional Variations
| Region |
Typical Cost Range (USD) |
Comment |
| United States / Canada |
$15 – 120 million |
Higher labor and regulatory costs; often requires more stringent GMP documentation. |
| Europe (EU) |
$12 – 110 million |
Similar to North America but can be slightly lower in some central/ Eastern EU locations due to lower labor costs. |
| Asia (India, China, Thailand) |
$6 – 60 million |
Lower labor & land costs can reduce the overall budget, but quality‑control and regulatory compliance remain expensive. |
Why the wide range?
• Production capacity: A plant that can produce 5 t/year will cost far less than a 100 t/year facility.
• Automation level: Fully automated, robotics‑heavy lines are considerably more expensive.
• Clean‑room classification: For small molecules like Ranolazine, a Class 1000 (ISO 8) clean‑room is usually sufficient, but higher‑grade rooms raise costs.
• Local regulations: Some countries have more rigorous GMP inspection schedules or require additional environmental safeguards.
Cost of Operating vs. Capital
| Item |
Capital (one‑time) |
OPEX (annual) |
| Facility & equipment |
$10‑120 M |
— |
| Raw materials (API) |
— |
~ $2‑$8 per gram of API produced |
| Utilities (electricity, water, compressed air) |
— |
$0.3‑$0.6 per kg of finished product |
| Labor & quality assurance |
— |
$1‑$2 per kg of finished product |
| Regulatory & compliance |
— |
$0.1‑$0.3 per kg (incl. inspections, audits) |
These OPEX figures are highly variable; a high‑automation line with robust PAT may lower per‑unit labor costs but increase upfront CAPEX. Conversely, a smaller plant may have higher labor costs per kilogram.
Bottom Line
- Small‑scale GMP plant: $7–$15 M (10–20 kg/day).
- Mid‑scale GMP plant: $15–$40 M (50–200 kg/day).
- Large‑scale GMP plant: $40–$120 M (≥ 200 kg/day).
If you’re planning a run‑of‑the‑mill Ranolazine facility, the most cost‑efficient route is often to partner with an existing contract‑manufacturing organization (CMO) that already has the required GMP infrastructure. CMOs can provide the entire production chain—from synthesis to formulation—at a cost that scales with production volume but typically eliminates the capital expenditure of building a new plant.
Tip for Decision‑Making
Before you lock into a build‑or‑buy decision, run a detailed cost‑benefit analysis that includes:
- Projected annual sales (to estimate required production capacity).
- Regulatory timeline (how quickly you need to be on‑market).
- Supply‑chain security (risk of single‑source API suppliers).
- Potential tax incentives (many countries offer R&D and manufacturing credits).
If you need deeper financial modeling, most pharma consulting firms offer “facility cost‑estimation” packages that factor in all these variables. Feel free to ask if you’d like a more granular walk‑through of any of the items above!